je.st
news
FDA Approves BELSOMRA (suvorexant) for the Treatment of Insomnia
2014-08-13 22:49:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. BELSOMRA expected to be available in late 2014 or early 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Megan Wilkinson, 267-305-6463orInvestor Contacts:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: treatment
fda
approves
insomnia
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||